ALHEMO (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
ALHEMO
Date registered
Evaluation commenced
Decision date
Approval time
218 (255 working days
Active ingredients
concizumab
Registration type
NCE/NBE
Indication
Alhemo is indicated where prophylaxis is required to prevent or reduce the frequency of bleeding in patients at least 12 years of age who have:
haemophilia A (congenital factor VIII [FVIII] deficiency) with FVIII inhibitors